Pilar Ausín

Pilar Ausín

Auto-generated profile, based on publicly available information

Pilar Ausín

Pulmonology Department, Hospital del Mar, 08003 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
EPEster Puig-Vilanova
Ester Puig-Vilanova
DRDiego A. Rodriguez
Diego A. Rodriguez
JLJosep Lloreta
Josep Lloreta
PAPilar Ausin
Pilar Ausin
SPSergio Pascual-Guardia
Sergio Pascual-Guardia
ESTHER BARREIROESTHER BARREIRO
ESTHER BARREIRO

9 March 2012 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
CFClara Fermoselle
Clara Fermoselle
RRRoberto Rabinovich
Roberto Rabinovich
PAPilar Ausín
Pilar Ausín
EPEster Puig-Vilanova
Ester Puig-Vilanova
CCCarlos Coronell
Carlos Coronell
ESTHER BARREIROESTHER BARREIRO
ESTHER BARREIRO
Oxidative stress may differentially regulate protein loss within peripheral muscles of severe chronic obstructive pulmonary disease (COPD) patients exhibiting different body composition.Oxidation levels of proteins, myosin heavy chain (MyHC) and myonuclei, superoxide anion, antioxidants, actin, creatine kinase, carbonic anhydrase-3, ubiquitin–proteasome system, redox-signalling pathways, inflammation and muscle structure, and damage were quantified in limb muscles of severe COPD patients with and without muscle wasting, and in sedentary controls.Compared with controls, in the quadriceps of muscle-wasted COPD patients, levels of protein carbonylation, oxidation of MyHC and myonuclei, superoxide anion production, superoxide dismutase, total protein ubiquinitation, E214k, atrogin-1, FoxO1 and p65 were higher, while content of MyHC, creatine kinase, carbonic anhydrase-3, myogenin, and fast-twitch fibre size were decreased. Importantly, in nonwasted COPD patients, where MyHC was more oxidised than in controls, its content was preserved. Muscle inflammation and glutathione levels did not differ between patients and controls. In all patients, muscle structure abnormalities were increased, while muscle force and exercise capacity were reduced.In severe COPD, while muscle oxidative stress increases regardless of their body composition, protein ubiquitination and loss of MyHC were enhanced only in patients exhibiting muscle atrophy. Oxidative stress does not seem to directly modulate muscle protein loss in these patients.

1 March 2010 in Thorax
Verified
Journal Article
Closed access
PPP. Paredi
P. Paredi
MGM. Goldman
M. Goldman
AAA. Alamen
A. Alamen
PAP. Ausin
P. Ausin
OUO. S Usmani
O. S Usmani
PBPeter Barnes
Peter Barnes
The usual analysis of forced oscillometry measures respiratory resistance (Rrs) and reactance (Xrs) averaged over several tidal breaths (whole-breath analysis). Recent within-breath analyses have separated Rrs and Xrs into their mean inspiratory and mean expiratory components (inspiratory-expiratory breath analysis) but these have not been used to compare patients with asthma and those with chronic obstructive pulmonary disease (COPD). Large inspiratory-expiratory variations in Xrs at 5 Hz (DeltaX5) in an individual have been used as a surrogate marker of expiratory flow limitation. Whole-breath and inspiratory-expiratory impulse oscillometry was assessed in 34 patients with asthma (49 + or - 3 years; 15 male, forced expiratory volume in 1 s (FEV(1)) 69 + or - 4% predicted), 48 patients with COPD (64 + or - 2 years; 32 male, FEV(1) 59 + or - 3% predicted) and 18 normal subjects (37 + or - 2 years; 8 male). Whole-breath analysis failed to discriminate between patients with asthma and patients with COPD either for all patients or for patients with FEV(1) <60% predicted. Inspiratory-expiratory analysis in patients with FEV(1) <60% predicted showed that in the COPD group mean expiratory X5 (-0.44 + or - 0.04 kPa/l/s) was greater than inspiratory X5 (-0.23 + or - 0.02 kPa/l/s, p<0.001) whereas patients with asthma did not show such changes (-0.36 + or - 0.07 kPa/l/s vs -0.26 + or - 0.03 kPa/l/s, p=0.23). Even though DeltaX5 was larger in patients with COPD (0.21 + or - 0.03 kPa/l/s) than in patients with asthma (0.10 + or - 0.07 kPa/l/s), this was not significant (p=0.15). Whole-breath impulse oscillation system analysis failed to discriminate between patients with asthma and those with COPD. Inspiratory-expiratory X5 analysis differentiated patients with asthma from those with COPD presumably reflecting enhanced dynamic airway narrowing on expiration in COPD. Further studies are needed to confirm these differences and investigate their cause.

1 June 2005 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
AAAbel Gómez-Caro Andrés
Abel Gómez-Caro Andrés
FDFrancisco Javier Moradiellos Díez
Francisco Javier Moradiellos Díez
PHPilar Ausín Herrero
Pilar Ausín Herrero
VGVicente Díaz-Hellín Gude
Vicente Díaz-Hellín Gude
ECEmilio Larrú Cabrero
Emilio Larrú Cabrero
JNJosé Luis Martín De Nicolás
José Luis Martín De Nicolás

27 March 2015 in Clinical Science
Verified
Journal Article
Closed access
PDF file
EPEster Puig-Vilanova
Ester Puig-Vilanova
JMJuana Martínez-Llorens
Juana Martínez-Llorens
PAPilar Ausin
Pilar Ausin
JRJosep Roca
Josep Roca
JGJoaquim Gea
Joaquim Gea
ESTHER BARREIROESTHER BARREIRO
ESTHER BARREIRO
The study reports novel findings on the associations of muscle weakness and atrophy with a differential expression profile of epigenetic events in the quadriceps of patients with advanced COPD, which was not seen in patients without muscle weakness.

23 March 2012 in Journal of Asthma
Verified
Journal Article
Closed access
MVMaría Del Carmen Vennera
María Del Carmen Vennera
LLLuis Pérez De Llano
Luis Pérez De Llano
SBSantiago Bardagí
Santiago Bardagí
PAPilar Ausin
Pilar Ausin
CSCarles Sanjuas
Carles Sanjuas
OROn Behalf Of The Spanish Registry
On Behalf Of The Spanish Registry
Objective. The efficacy of omalizumab in severe asthma has been widely demonstrated. The main objective of this study was to evaluate the efficacy and tolerability of omalizumab in a real-life setting in Spain, particularly in those patients with immunoglobulin E (IgE) levels out of range. Methods. Totally 266 uncontrolled severe asthma patients receiving high-dose inhaled corticosteroids (ICSs) plus long-acting β2-agonist (LABA) were recruited. Main efficacy outcomes were asthma exacerbation rate (AER), asthma control test (ACT), and global evaluation of treatment effectiveness (GETE). Results. AER was reduced from 3.6 (3.6) in previous year to 0.67 (1.2) at 4 months (p < .05) and to 1.04 (1.8) at 2 years (p < .05). ACT increased significantly from 14.3 (4.7) at baseline to 18.4 (4.4) at 4 months (p < .05) and to 20.3 (4.0) (p < .05) at 2 years. After 4 months, 74.6% of patients had reached a good or excellent rate on the GETE scale (p < .05). This rate continued increasing up to 81.6% at 2 years. These efficacy results were similar for patients with “off-label” IgE > 700 IU/ml. At follow-up, maintenance treatment with oral steroids was discontinued in a considerable number of patients: from 89 to 19 (p < .05). Omalizumab was discontinued because of lack of efficacy only in 28/266 (10.5%) patients. Overall, 30 patients (11.4%) reported adverse events. Severe adverse events were not observed. Conclusion. This real-life study confirms that omalizumab is very efficacious and very well tolerated in patients with uncontrolled severe asthma. Results did not vary in the subgroup of patients with IgE levels >700 IU/ml.